Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.30 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbon Monoxide SCHEMBL3010268 | 0.88 | TSHR (0.32) | TSHRLMNATHRB | |
| SCHEMBL7899273 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL1459603 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL6241582 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL31171921 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL4489669 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL31171990 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL6033481 | 0.87 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL6884514 | 0.78 | CA12 (0.33) | — | |
| Hydrochloric Acid SCHEMBL11611172 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | disclosed |
| EP-2344157-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344158-A1 | Use of isoQC inhibitors | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | TSHR 1599/4885LMNA 3707/4885THRB 1219/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | TSHR 4798/4885LMNA 3611/4885THRB 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.